This inventor holds 17 USPTO granted patents and 27 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Adeno-Associated Virus. Top assignees: University of Florida Research Foundation Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2000-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Gainsville, FL (US) (2017)
- Gainesville, FL (US) (2000 - 2022)
Company Filing History:
17 out of 3,058 
1 out of 3,699 
Years Active: 2000-2026
Areas of Expertise:
Title: The Innovative Contributions of Barry John Byrne
Introduction
Barry John Byrne, based in Gainesville, FL, is a prolific inventor with an impressive portfolio of 15 patents. His work primarily focuses on advancements in gene therapy and adeno-associated viruses, showcasing his commitment to improving therapeutic options for various genetic conditions.
Latest Patents
Among his most recent innovations are two notable patents. The first, titled "Methods of packaging multiple adeno-associated virus vectors," outlines techniques for co-packaging various recombinant adeno-associated virus (rAAV) particles. This method enables the introduction of multiple nucleic acid vectors encoding desired proteins or RNAs into a single cell preparation, enhancing the efficacy of gene delivery systems. The second patent, "AAV vector for treatment of Friedreich's ataxia," involves compositions and methods geared towards treating this hereditary disease. The patented technique integrates nucleic acids and recombinant adeno-associated viral particles, particularly utilizing a FXN coding sequence and a truncated FXN 3' UTR, demonstrating Byrne's focus on tackling complex genetic disorders.
Career Highlights
Barry John Byrne has had a noteworthy career journey, particularly through his roles at the University of Florida and the University of Florida Research Foundation. His research initiatives have significantly contributed to advancements in gene therapy, solidifying his status as a key figure in the field.
Collaborations
Throughout his career, Byrne has collaborated with esteemed colleagues, including Sergei Zolotukhin and Nicholas Muzyczka. These partnerships have enhanced his research endeavors and fostered the development of innovative solutions in genetic therapies.
Conclusion
Barry John Byrne exemplifies the spirit of innovation through his extensive patent portfolio and collaborative efforts in the field of gene therapy. His dedication to addressing genetic disorders through advanced methods continues to inspire future innovations and contributes to the ongoing evolution of medical research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile